Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Xeruborbactam oral prodrug (QPX7831) with ceftibuten in healthy volunteers
NCT06079775Phase 1Completed
- Sponsor
- Qpex Biopharma
- Start
- Jan 2024
- Primary completion
- Jan 2025
- Modality
- Reversible Covalent Inhibitors
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of xeruborbactam in bacterial infection (4 arms), sponsored by Qpex Biopharma. Primary endpoints: Treatment-Emergent Adverse Events at 16 days, Changes from Baseline in Safety Parameters at 16 days and 5 more. Started Jan 2024; status: completed.
02
Drugs
xeruborbactam
03
Conditions
bacterial infection
Beyond the preview
Go deeper on NCT06079775.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06079775.